- Home
- ERIE vs JAZZ Comparison
ERIE vs JAZZ Comparison
Compare ERIE & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERIE | JAZZ |
|---|---|---|
| Founded | 1925 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | 2890 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 15.0B |
| IPO Year | 2011 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ERIE | JAZZ |
|---|---|---|
| Price | $226.43 | $239.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $217.57 |
| AVG Volume (30 Days) | 128.6K | ★ 805.3K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 491.00 | 4.43 |
| Revenue | ★ $1,691,774,000.00 | $1,618,693,000.00 |
| Revenue This Year | $6.83 | $6.22 |
| Revenue Next Year | N/A | $7.68 |
| P/E Ratio | ★ $0.45 | $54.21 |
| Revenue Growth | ★ 5.96 | N/A |
| 52 Week Low | $204.63 | $105.00 |
| 52 Week High | $380.67 | $243.32 |
Technical Indicators
Market Signals| Indicator | ERIE | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 63.12 |
| Support Level | $210.07 | $128.87 |
| Resistance Level | $229.13 | $243.32 |
| Average True Range (ATR) | 6.25 | 6.14 |
| MACD | 1.24 | -1.26 |
| Stochastic Oscillator | 89.63 | 72.42 |
Price Performance
Historical ComparisonAbout ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.